EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Continuing to ignore the problem of the know-how gap won’t make it go away.
The Covid-19 pandemic was a wake-up call for a variety of issues in access to medicines, one of which was finding a solution to...
Sharing know-how/trade secrets during a pandemic: We must be planning for it now
Medicines Law & Policy has recently proposed a provision for inclusion in the draft WHO pandemic instrument currently being discussed in Geneva (here and...
European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and...
European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...
How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine
The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not...
Opmerkingen bij de notitie Dwanglicenties van B.J. Bruins, Minister voor Medische Zorg.
Op 15 juni 2018 stuurde Minister Bruins een notitie over dwanglicenties aan de Tweede Kamer. In deze briefing maken wij een aantal voorlopige opmerkingen...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?
Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....